CFI-400945 rexol 18-37)46-28)12-11-27(44-34)33(8)13-14-35(47-33)17-25(38)22(5)30(45-35)23(6)29(42-9)24(7)32(39)40/h19-31

18-37)46-28)12-11-27(44-34)33(8)13-14-35(47-33)17-25(38)22(5)30(45-35)23(6)29(42-9)24(7)32(39)40/h19-31

Parkinson’s disease

Smiles: CC1N=C(SC=1C(=O)NCC1C=NC=CC=1)N1CCN(CC2C=CC(F)=CC=2)C1=O

24 hours) exhibits general cytostatic but type-specific cytotoxic effects for melanoma cells

0]oct-2-en-3-yl]methyl}-1-{2-[(2-chloro-3

CFI-400945 rexol 18-37)46-28)12-11-27(44-34)33(8)13-14-35(47-33)17-25(38)22(5)30(45-35)23(6)29(42-9)24(7)32(39)40/h19-31CFI 400945 is an orally active, potent and selective inhibitor of polo like kinase 4. Polo like kinase 4 (PLK4), a unique member of the Polo like family of kinases, shares little homology with other polo like kinases. PLK4 plays an essential role in centriole duplication. Overexpression of PLK4 overrides the centriole licensing mechanism and results in centriole amplification with multiple procentrioles forming around each parental centriole.